- Poster presentation
- Open Access
IFN-α2b reduces released particles of Human T-lymphotropic Virus-I from HTLV-I transformed cell line
© Hartoonian et al; licensee BioMed Central Ltd. 2011
- Published: 3 October 2011
- Post Treatment
- Spastic Paraparesis
- Transformed Cell Line
- Alpha IFNs
- Antiviral Mechanism
HTLV-I is causative agent of Acute T-cell Leukemia (ATL) and HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). To date there isn't an established treatment available for HTLV-I infection. Type-I IFNs are well known for their antiviral, anti proliferative and immunomodulatory effects. Antiviral mechanism of these IFNs varies depending on the virus and host type and could fluctuate between virus entry to its replication and release. IFN-α 2b is qualified for treatment of Hepatitis B and C and some malignancies such as specific leukemias and lymphomas. There are few clinical trials indicating type-l IFNs efficacy in HTLV-I infected patients, nevertheless a few studies have focused on antiviral mechanism of alpha IFNs on HTLV-I.[2, 3] Here we report the reducing effect of IFN-α 2b (PDferon®-B) on released particles of HTLV-I by HTLV-I transformed MT2 cell line.
MT2 cells were treated with 1000 U/ml of IFN-α 2b ( PDferon®-B). 12 and 36 hours post treatment, MT2 cells were collected and cell lysates were analyzed for expression of HTLV-I Gag, Tax and HBZ genes by gene specific primers utilizing real time RT-PCR method .As a representative of HTLV-I free particles released in supernate by MT2 cells, virus Gag gene copy number in supernate was evaluated at aforementioned hours post treatment.
There was no significant difference in expression of HTLV-I Gag, Tax and HBZ genes between cell lysates of treated and untreated MT2 cells at both 12 and 36 hours post treatment. At 12 hours post treatment, released Virus titer was not changed in supernate of treated cells while a significant decrease in viral particles was observed in collected supernate of treated cells at 36 hours after treatment with IFN-α2b.
Our result shows that IFN-α2b (PDferon®-B) treatment does not have any effect on expression of both structural and non structural genes of HTLV-I at 12 and 36 hours of treatment thus Reduction of HTLV-I titer at the 36th hour post treatment suggests that IFN-α2b ( PDferon®-B) does not exert its antiviral effects at viral transcription level. The significant decrease in viral titer in supernate by IFN-α 2b ( PDferon®-B) could be due to its interfering effect at any posttranscriptional level. Our results are in accordance with previous studies that have shown the similar effects of other members of type-l IFN family such as IFNα2a. The exact mechanism by which this IFN has exerted its effects is yet to be clarified by details. Outcome of such extended studies would be of paramount importance in using IFN-α 2b in treatment of HTLV-I infection.
- Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haider JH, Hermine O, de The H: Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in Human T-cell Lymphotropic Virus Type I transformed cells. Blood. 1999, 93: 278-283.PubMedGoogle Scholar
- Xuan Feng NVH, Ratner L: Alpha interferon inhibits humanT-cell leukemia virus type-l assembly by preventing Gag interation with rafts. J Virol. 2003, 77: 13389-13395. 10.1128/JVI.77.24.13389-13395.2003.View ArticleGoogle Scholar
- D'Onofrio , Perno CF, Mazzetti P, Graziani G, Calio R, Bonmassar E: Depression of early phase of HTLV-I infection in vitro mediated by human beta-interferon. Br J Cancer. 1988, 481-488.Google Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.